DFTX Key Statistics, Chart & Performance
The current stock price of DFTX is 16.9 USD.
DFTX Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to DFTX.
DFTX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to DFTX. While DFTX seems to be doing ok healthwise, there are quite some concerns on its profitability.
DFTX Financial Highlights
Over the last trailing twelve months DFTX reported a non-GAAP Earnings per Share(EPS) of -1.96. The EPS increased by 13.27% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -70.95% | ||
| ROE | -128.72% | ||
| Debt/Equity | 0.31 |
DFTX Forecast & Estimates
DFTX Ownership
DFTX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 31.53 | 965.082B | ||
| JNJ | JOHNSON & JOHNSON | 20.76 | 572.907B | ||
| MRK | MERCK & CO. INC. | 22.54 | 297.222B | ||
| PFE | PFIZER INC | 9.06 | 150.614B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 10.19 | 121.168B | ||
| ZTS | ZOETIS INC | 18.6 | 55.849B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.61 | 25.456B | ||
| VTRS | VIATRIS INC | 5.78 | 16.516B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.9 | 12.079B | ||
| AXSM | AXSOME THERAPEUTICS INC | 223.48 | 9.116B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About DFTX
Company Profile
Definium Therapeutics Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in New York City, New York and currently employs 74 full-time employees. The company went IPO on 2015-05-04. Definium Therapeutics, Inc., formerly Mind Medicine (MindMed) Inc., is engaged in developing therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. The firm plans to advance DT1201 ODT toward FDA submissions in the two largest psychiatric markets, generalized anxiety disorder (GAD) and major depressive disorder (MDD). Its late-stage pipeline includes four Phase 3 trials, two each for GAD and MDD, anchored by its lead candidate, DT120 ODT, which has received an FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is engaged in advancing its commercial strategy and operational readiness to support a care model and prepare for the launch of DT120 ODT, if approved and marketed. The company also continues to advance its early-stage pipeline, having dosed the first patient in a Phase 2a study of DT4023 in adults with autism spectrum disorder (ASD).
Company Info
DEFINIUM THERAPEUTICS INC
One World Trade Center, Suite 8500
New York City NEW YORK US
Employees: 74
Phone: 12122206633
DEFINIUM THERAPEUTICS INC / DFTX FAQ
Can you describe the business of DEFINIUM THERAPEUTICS INC?
Definium Therapeutics Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in New York City, New York and currently employs 74 full-time employees. The company went IPO on 2015-05-04. Definium Therapeutics, Inc., formerly Mind Medicine (MindMed) Inc., is engaged in developing therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. The firm plans to advance DT1201 ODT toward FDA submissions in the two largest psychiatric markets, generalized anxiety disorder (GAD) and major depressive disorder (MDD). Its late-stage pipeline includes four Phase 3 trials, two each for GAD and MDD, anchored by its lead candidate, DT120 ODT, which has received an FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is engaged in advancing its commercial strategy and operational readiness to support a care model and prepare for the launch of DT120 ODT, if approved and marketed. The company also continues to advance its early-stage pipeline, having dosed the first patient in a Phase 2a study of DT4023 in adults with autism spectrum disorder (ASD).
What is the stock price of DEFINIUM THERAPEUTICS INC today?
The current stock price of DFTX is 16.9 USD. The price increased by 4% in the last trading session.
Does DEFINIUM THERAPEUTICS INC pay dividends?
DFTX does not pay a dividend.
How is the ChartMill rating for DEFINIUM THERAPEUTICS INC?
DFTX has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Where is DEFINIUM THERAPEUTICS INC (DFTX) stock traded?
DFTX stock is listed on the Nasdaq exchange.
Can you provide the short interest for DFTX stock?
The outstanding short interest for DEFINIUM THERAPEUTICS INC (DFTX) is 17.29% of its float.